Rocbrutinib and Lacutoclax for B-Cell Blood Cancers
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of two new drugs (rocbrutinib and lacutoclax) to treat B-cell lymphomas and leukemias. The goal is to see if this combination works better than standard treatments, especially for patients whose cancer has come back or stopped responding to previous therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Confirmed B-cell cancer diagnosis (such as CLL, SLL, MCL, DLBCL, FL, or WM) with disease progression or intolerance to prior treatment (or treatment-naïve CLL/SLL meeting treatment criteria)
- At least one measurable tumor lesion that can be tracked on imaging
- Good overall health status and life expectancy of at least 12 weeks
- Normal blood clotting, liver, kidney, and bone marrow function
- Willing to use effective birth control during the study and 90 days after (if applicable) and commit to study visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy, Rocbrutinib, for a specific type of aggressive B-cell lymphoma (non-GCB DLBCL) that has not responded to or returned after two or more prior treatments. It aims to see if Rocbrutinib can help people who have few other options.
This trial tests a combination of three drugs (orelabrutinib, lisaftoclax, and rituximab) for people with mantle cell lymphoma who have not had treatment before and have high-risk features. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of two targeted drugs for people with mantle cell lymphoma that has come back or stopped responding after prior treatment with a BTK inhibitor. The goal is to see if this new combination can effectively shrink tumors.
This trial is testing a combination of two targeted drugs, orelabrutinib and rituximab, as a first treatment for mantle cell lymphoma (MCL). Some patients may also get a stem cell transplant. The goal is to see how well this approach works.
This trial tests a combination of two targeted drugs (acalabrutinib and rituximab) for people with mantle cell lymphoma who have not had treatment before. It is designed for older patients or younger patients with a less aggressive form of the disease.
This trial tests a new combination of three targeted drugs (orelabrutinib, obinutuzumab, and venetoclax) for people with newly diagnosed mantle cell lymphoma who have not had treatment before. The goal is to see if this short-course combination can effectively control the disease while being gentle on the body.
Hear when a new Waldenström Macroglobulinemia (WM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.